Quantcast

Latest Ibritumomab tiuxetan Stories

2010-06-11 00:30:00

SEATTLE, June 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (the "Company") (Nasdaq and MTA: CTIC) today reported exploratory analyses of the data at study completion from the Company's pivotal PIX301 trial of Pixuvri(TM) (pixantrone dimaleate), the first randomized controlled trial in patients with relapsed or refractory, aggressive non-Hodgkin's lymphoma ("NHL"). These analyses demonstrated that patients who achieved a complete response (CR)/unconfirmed complete response (CRu) to...

2010-06-08 11:27:09

Molecular imaging is leading to more individualized and effective treatment for non-Hodgkin's lymphoma by providing a map to guide the path of therapy According to a study presented at SNM's 57th Annual Meeting, molecular imaging can evaluate and optimize non-Hodgkin's lymphoma therapy with Zevalin, a front-line radioimmunotherapy drug that uses a dose of radioactive material and mimics the body's own immune response to target and kill cancer cells while sparing nearby healthy tissues. "By...

2010-02-11 00:30:00

SEATTLE, Feb. 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today reported recent accomplishments and financial results for the fourth quarter and year ended December 31, 2009. Review of 2009 Key Accomplishments and Targeted 2010 Milestones Pixantrone New Drug Application ("NDA") for relapsed/refractory aggressive non-Hodgkin's lymphoma filed with the U.S. Food and Drug Administration (the "FDA") and accepted for review in 2009. The FDA established...

2009-12-02 00:30:00

SEATTLE, Dec. 2 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that Ruth Pettengell, M.D. of St. George's Hospital, University of London, the lead investigator for the PIX 301 EXTEND trial will present new data on the pixantrone phase III trial in relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL) at the 51st Annual Meeting of the American Society of Hematology on Saturday, December 5, 2009 in New Orleans, Louisiana. The...

2009-11-05 11:09:00

NEW YORK, Nov. 5 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Monoclonal Antibody Therapies 2007: Competitive Landscape and Pipeline Insight http://www.reportlinker.com/p0158341/Monoclonal-Antibody-Therapies-2007-Competitive-Landscape-and-Pipeline-Insight.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire In 2005, the antibodies market was valued at an estimated US$14 billion, accounting for over 24...

2009-10-22 00:30:00

SEATTLE, Oct. 22 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that Dr. Richard Van der Jagt of the Ottawa General Hospital will present at the Lymphoma and Myeloma 2009 Conference in New York an overview of CTI's pixantrone phase II and phase III clinical studies that demonstrated high rates of complete remission (CR) in relapsed/refractory aggressive and indolent non-Hodgkin's lymphoma (NHL) patients. Highlights from the presentation...

2009-09-16 00:30:00

SEATTLE, Sept. 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today released updated 18-month follow-up clinical data for its phase III EXTEND (PIX 301) trial of pixantrone (BBR2778) for patients with advanced, relapsed or refractory, aggressive non-Hodgkin's lymphoma (NHL). Responses were evaluated by an Independent Assessment Panel that was blinded to patient assignment. The table below shows the primary end of treatment data analyses previously...

2009-06-22 00:30:00

SEATTLE, June 22 /PRNewswire-FirstCall/ -- Updated follow-up phase III EXTEND (PIX 301) clinical trial data enhances previously reported superior response rates for pixantrone over comparator including in high risk patient subgroups Additional Clinical Studies Also Highlighted at Pan Pacific Conference Randomized phase III; PIX 302-Pixantrone plus rituximab significantly improves CR rate (35% vs. 11%), ORR (75% vs. 33%) and time to progression (TTP) (13.2 vs. 8.1 months) compared to...

2009-06-08 00:24:00

- Afinitor significantly reduced tumor size by 50% or more in one out of three patients with refractory or relapsed lymphoma - Phase III study underway to explore potential of Afinitor to prevent relapse in patients with the most common type of non-Hodgkin's lymphoma EAST HANOVER, N.J., June 8 /PRNewswire/ -- New data show that Afinitor(R) (everolimus) tablets significantly shrunk tumors in 33% of patients with relapsed non-Hodgkin's lymphoma (NHL) and Hodgkin's disease(1). Based on...

2009-05-07 00:30:00

Pixantrone Named-Patient Program Initiated in Europe SEATTLE, May 7 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) reported recent accomplishments and financial results for the quarter ended March 31, 2009. "Our focus for the first half of 2009 was to initiate and complete the NDA submission for pixantrone while we implemented final steps in our cost cutting efforts and raised much needed operating capital on the least dilutive terms possible -- all while...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related